PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Ra...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Medicine (Baltimore)
Egile Nagusiak: Wang, Man Cai, Zhang, Ling Yi, Han, Wei, Shao, Yuan, Chen, Mo, Ni, Rui, Wang, Gen Nian, Wei, Feng Xian, Zhang, Ya Wu, Xu, Xiao Dong, Zhang, You Cheng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2014
Gaiak:
4200
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603082/
https://ncbi.nlm.nih.gov/pubmed/25526490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000326
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak